Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Thatcher

Showing results (281-290 of 289) with videos related to

Pageof 29
Sort By:
You have reached the last page of results.This site can display upto 289 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancerC Manegold, N van Zandwijk, A Szczesna, et al.
Lung Cancer (Amsterdam, Netherlands)|September 3, 2013
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancerT Ciuleanu, C-M Tsai, C-J Tsao, et al.
British Journal of Cancer|November 20, 1998
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanomaM R Middleton, J M Lunn, C Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patientsU Keilholz, C Conradt, S S Legha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaM R Middleton, J J Grob, N Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancerE F Smit, M A Socinski, B P Mullaney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancerT Brodowicz, T Ciuleanu, J Crawford, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomesT Le Chevalier, G Scagliotti, R Natale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerP D Bonomi, D Gandara, F R Hirsch, et al.
Pageof 29

Showing results (281-290 of 289) with videos related to

Sort By:
Pageof 29
You have reached the last page of results.This site can display upto 289 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancerC Manegold, N van Zandwijk, A Szczesna, et al.
Lung Cancer (Amsterdam, Netherlands)|September 3, 2013
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancerT Ciuleanu, C-M Tsai, C-J Tsao, et al.
British Journal of Cancer|November 20, 1998
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanomaM R Middleton, J M Lunn, C Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patientsU Keilholz, C Conradt, S S Legha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaM R Middleton, J J Grob, N Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancerE F Smit, M A Socinski, B P Mullaney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancerT Brodowicz, T Ciuleanu, J Crawford, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomesT Le Chevalier, G Scagliotti, R Natale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerP D Bonomi, D Gandara, F R Hirsch, et al.
Pageof 29